ClinicalTrials HQ

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

Recruiting · NCT05784688 · Registry updated 2025-03-30
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsBiliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, biliary tract cancer, biliary tract disorder, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, head and neck squamous cell carcinoma, intestinal disorder, neoplasm, rectal disorder, squamous cell carcinomaRecruitingPhase 1 / Phase 22025-03-30NCT05784688

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Merck Sharp & Dohme LLC650
TiumBio Co., Ltd.2

11 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Asan Medical CenterSeoulSouth Korea131
CHA University Bundang Medical CenterSeongnamSouth Korea3
Hope Cancer CenterTylerUnited States1
Medical OncologySpokaneUnited States1
NEXT OncologySan AntonioUnited States1
Samsung Medical CenterSeoulSouth Korea170
Seoul National University Bundang HospitalSeongnamSouth Korea42
Seoul National University HospitalSeoulSouth Korea183
Severance HospitalSeoulSouth Korea62
The Catholic University of Korea Seoul St. Mary HospitalSeoulSouth Korea1
The Catholic University Of Korea St. Vincent's HospitalSuwonSouth Korea4